"Hemostasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
| Descriptor ID |
D006487
|
| MeSH Number(s) |
G09.188.390
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hemostasis".
Below are MeSH descriptors whose meaning is more specific than "Hemostasis".
This graph shows the total number of publications written about "Hemostasis" by people in this website by year, and whether "Hemostasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemostasis" by people in Profiles.
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
-
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
-
Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
-
The Hemocompatibility of Nanoparticles: A Review of Cell-Nanoparticle Interactions and Hemostasis. Cells. 2019 10 07; 8(10).
-
The Hemostatic Conundrum of Thrombotic Thrombocytopenic Purpura: a Case Report. Clin Lab. 2019 Jun 01; 65(6).
-
rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
-
Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May; 24 Suppl 6:15-21.
-
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
-
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.